Design and Synthesis of 4-Heteroaryl 1,2,3,4-Tetrahydroisoquinolines as Triple Reuptake Inhibitors
作者:Shuang Liu、Congxiang Zha、Kassoum Nacro、Min Hu、Wenge Cui、Yuh-Lin Yang、Ulhas Bhatt、Aruna Sambandam、Matthew Isherwood、Larry Yet、Michael T. Herr、Sarah Ebeltoft、Carla Hassler、Linda Fleming、Anthony D. Pechulis、Anne Payen-Fornicola、Nicholas Holman、Dennis Milanowski、Ian Cotterill、Vadim Mozhaev、Yuri Khmelnitsky、Peter R. Guzzo、Bruce J. Sargent、Bruce F. Molino、Richard Olson、Dalton King、Snjezana Lelas、Yu-Wen Li、Kim Johnson、Thaddeus Molski、Anitra Orie、Alicia Ng、Roy Haskell、Wendy Clarke、Robert Bertekap、Jonathan O’Connell、Nicholas Lodge、Michael Sinz、Stephen Adams、Robert Zaczek、John E. Macor
DOI:10.1021/ml500053b
日期:2014.7.10
series of 4-bicyclic heteroaryl 1,2,3,4-tetrahydroisoquinoline inhibitors of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT) was discovered. The synthesis and structure-activity relationship (SAR) of these triple reuptake inhibitors (TRIs) will be discussed. Compound 10i (AMR-2), a very potent inhibitor of SERT, NET, and DAT, showed efficacy in the
发现了一系列5-羟色胺转运蛋白(SERT),去甲肾上腺素转运蛋白(NET)和多巴胺转运蛋白(DAT)的4-双环杂芳基1,2,3,4-四氢异喹啉抑制剂。将讨论这些三重再摄取抑制剂(TRIs)的合成和构效关系(SAR)。化合物10i(AMR-2)是一种非常有效的SERT,NET和DAT抑制剂,在大鼠强迫游泳和小鼠尾巴悬液模型中分别以0.3和1 mg / kg(po)的最小有效剂量显示了功效。在这些测定中的有效剂量下,10i在大鼠和小鼠脑中的三个转运蛋白上均表现出明显的占用水平。对10i代谢的研究表明形成了重要的活性代谢产物化合物13。